secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2025-07-09T23:59:59+00:00
Accession:  0001641172-25-018403
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa enters warrant exercise inducement; expected gross proceeds ~$2.05M
---------------------------------------------------------------------------

- Existing Series A-2 and A-3 warrants with $1 exercise price reduced to $0.67; holder exercises for cash.
- Company issues new Series A-4 warrants to purchase 200% of exercised shares, $0.67 exercise price, 5-year term.
- If all warrants exercised, gross proceeds ~$2.05 million; proceeds for working capital.
- Issuance of inducement warrant shares subject to stockholder approval; registration statement to be filed by August 8, 2025.
- AGP acts as financial advisor, receiving 6.5% cash fee of aggregate gross proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000164117225018403/0001641172-25-018403-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000164117225018403/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-018403

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer